NEXUS AG (0FGL) AI Stock Analysis

• Market Cap: €1.25B
• Dividend Yield: 0.32%
• Average Volume (3M): 3.00
• Price to Earnings (P/E): 37.6
• Beta (1Y): 0.07
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 1,909
• Sector: Financial
• Sector Strength: 82
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.48
• Shares Outstanding: 17,274,694
• 10 Day Avg. Volume: 10
• 30 Day Avg. Volume: 3
• PEG Ratio: 2.56
• Price to Book (P/B): 4.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 29.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €70.00
• Price Target Upside: -1.13% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

NEXUS AG Business Overview & Revenue Model

Company Description

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and KIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/REHAB for rehabilitation facilities; ITR, a software for rehabilitation, clinics, and hotels with medical care; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/QM for quality management; NEXUS/INTEGRATION SERVER, an interface management; NEXUS/CLOUD IT, outsourcing solution; NEXUS/EPS, a software solution to supplement SAP personnel management, as well as process and HR consulting in the SAP environment; ifa systems, an ophthalmology software solution; Sophrona solutions, ophthalmology patients and referral program; and NEXUS/DIS, interdisciplinary diagnostic information system. Its information systems also comprise NEXUS/SWISSLAB, a laboratory information system; NEXUS/LAURIS for order communication in diagnostics; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; dc-Pathos and dc-LabMan for pathology and cytology devices; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUs/CHILI, for PACS and teleradiology solutions; NEXUS/ASTRAIA for obstetrics and gynecology; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical specialist diagnostics and device integration; NEXUS/HOME for senior citizen and nursing homes; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/PAT, an administration system for hospitals; and osoTEC for billing personal and other services. In addition, the company offers SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS/EPD, NEXUS/AEMP, NEXUS/SPM, EuroSDS, RVS Software, NEXUS/VITA and TESIS VITA, and NEXUS/ESKULAP. NEXUS AG is headquartered in Donaueschingen, Germany.

How the Company Makes Money

NEXUS AG Financial Statement Overview

Summary

NEXUS AG exhibits strong financial performance with consistent revenue growth and solid cash flow generation. While the absence of EBIT in the latest report is a drawback, other profitability margins remain healthy. The balance sheet is characterized by low leverage and strong equity, ensuring financial stability. Robust cash flow metrics further underscore the company's operational efficiency and potential for sustained growth.

Income Statement

NEXUS AG has demonstrated consistent revenue growth with a solid revenue growth rate of 8.29% in the latest year. Gross profit margin is strong at 85.33%, though the lack of EBIT in the latest reporting year is a concern. EBITDA margin is healthy at 23.49%, indicating good operational efficiency. Net profit margin improved to 11.78%, showcasing enhanced profitability.

Balance Sheet

The company's balance sheet is stable with a low debt-to-equity ratio of 0.07, indicating low financial leverage. Return on Equity is decent at 11.03%, reflecting reasonable profitability relative to equity. The equity ratio stands at 63.82%, showcasing solid financial stability and a strong equity base.

Cash Flow

NEXUS AG shows a robust free cash flow growth rate of 96.38%, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.67, suggesting efficient conversion of income to cash. With a free cash flow to net income ratio of 1.34, the company effectively turns profits into cash, supporting sustainable operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
261.46M	241.46M	209.13M	188.18M	162.94M
	Gross Profit
223.09M	65.97M	176.46M	159.09M	141.60M
	EBIT
38.42M	24.77M	28.49M	24.27M	17.21M
	EBITDA
61.43M	53.43M	44.81M	40.77M	36.69M
	Net Income Common Stockholders
30.82M	24.03M	19.35M	17.15M	14.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
117.23M	99.00M	110.95M	26.30M	28.63M
	Total Assets
437.73M	411.72M	344.20M	247.34M	223.16M
	Total Debt
20.91M	20.25M	18.67M	16.63M	13.15M
	Net Debt
1.88M	2.81M	-1.35M	-9.54M	-13.29M
	Total Liabilities
154.77M	153.13M	105.25M	104.94M	99.58M
	Stockholders Equity
279.24M	255.09M	235.03M	138.79M	120.20M
Cash Flow		Free Cash Flow
41.15M	20.95M	28.30M	25.82M	25.60M
	Operating Cash Flow
51.54M	30.41M	33.88M	31.39M	30.95M
	Investing Cash Flow
-30.32M	-17.02M	-98.55M	-21.25M	-22.00M
	Financing Cash Flow
-19.63M	-16.72M	57.97M	-11.08M	-16.14M

NEXUS AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0FGL		€1.25B	37.60	11.87%	0.32%	―	―
Sector *	64 Neutral	$12.87B	9.81	7.76%	16985.65%	12.28%	-7.83%
0MSD		€1.16B	33.13	5.26%	4.52%	―	―
0HI7		€45.86M	10.83	24.14%	3.71%	―	―